Labcorp Holdings Inc. (NYSE:LH) Stock Has Consensus Price Target of $337.73

Labcorp Holdings Inc. (NYSE:LH) has been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $365.67.

Several research firms have weighed in on LH. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $355.00 price target on shares of Labcorp in a research note on Thursday. Morgan Stanley reaffirmed an “overweight” rating and set a $388.00 price objective on shares of Labcorp in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Weiss Ratings raised Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, October 21st.

Insiders Place Their Bets

In other news, EVP Amy B. Summy sold 924 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares of the company’s stock, valued at approximately $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kerrii B. Anderson sold 3,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the sale, the director directly owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. This trade represents a 31.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,593 shares of company stock valued at $2,733,295 in the last ninety days. Company insiders own 0.84% of the company’s stock.

Institutional Investors Weigh In On Labcorp

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in shares of Labcorp by 1.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock valued at $607,241,000 after purchasing an additional 22,170 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Labcorp by 2.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock worth $355,569,000 after purchasing an additional 28,584 shares in the last quarter. Royal Bank of Canada raised its holdings in Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after purchasing an additional 133,549 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Labcorp in the second quarter worth $168,222,000. Finally, Bessemer Group Inc. lifted its position in Labcorp by 47.3% during the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock valued at $154,493,000 after buying an additional 185,847 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Labcorp Trading Down 1.7%

LH stock opened at $361.96 on Monday. The company has a market capitalization of $29.35 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 2.09 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.53 and a current ratio of 1.41. Labcorp has a one year low of $244.52 and a one year high of $371.00. The company’s 50 day moving average price is $323.23 and its two-hundred day moving average price is $287.61.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $4.18 EPS. The firm’s revenue was up 6.9% on a year-over-year basis. As a group, analysts predict that Labcorp will post 18.46 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s dividend payout ratio (DPR) is presently 23.63%.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reported third-quarter adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue increased 6.9% year over year to $3.81 billion, topping expectations. The company also raised its outlook, supporting the investment case. Labcorp Q3 2026 Earnings Call Highlights
• Positive Sentiment: Truist raised its price target to $395 from $365 and maintained a Buy rating, while Robert W. Baird increased its target to $396 from $361 and retained an Outperform rating. The revisions indicate analysts see additional upside after the earnings beat. Truist Raises Labcorp Price Target
• Positive Sentiment: Zacks identified LH as a highly ranked value stock, potentially attracting investors seeking a combination of earnings strength and reasonable valuation characteristics. Labcorp Is a Top-Ranked Value Stock
• Neutral Sentiment: Labcorp’s estimated fair value moved modestly higher following third-quarter analyst revisions, suggesting improving expectations but limited near-term valuation support. Labcorp Fair Value Edges Higher
• Negative Sentiment: Analysts continue to flag potential pressure from changes to Medicare laboratory reimbursement rules under PAMA. That risk may temper the benefit of better earnings and guidance. Labcorp Stock Shrugs Off Q3 Earnings as PAMA Risk Looms
• Negative Sentiment: A Seeking Alpha contributor downgraded the stock, arguing that investor optimism and the sharp advance toward a 52-week high may have outpaced Labcorp’s underlying upside. Deutsche Bank raised its target to $355 but maintained a Hold rating, reinforcing valuation concerns. Labcorp Rating Downgrade

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.